Melasma Melasma, Melasma treatment, Triple combination cream, 5% Alpha-Arbutin, 2% Kojic acid
Conditions
Interventions
The patients were enrolled and randomized to triple combination cream on the other sided of face. The duration of treatment is twelve weeks, with four-weekly follow-ups throughout and after end of t
Experimental Drug,Experimental Drug
a topical containing 5% alpha-arbutin and 2% kojic acid ,triple combination cream
Sponsors
Institute of dermatology
Eligibility
Sex/Gender
All
Age
25 Years to 60 Years
Inclusion criteria
Inclusion criteria: adult between 25- 60 years having a clinical diagnosis of bilateral melasma.
Exclusion criteria
Exclusion criteria: allergic to alpha-arbutin, kojic acid, hydroquinone, tretinoin and fluocinolone acetonide, using medication including hydroquinone, azelaic acid, retinoid, tranexamic acid, skin care products containing AHA, Niacinamide, ascorbic acid, history of chemical peeling and LASER within three months prior to enrolling in the study, pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Melasma 4th wk, 8th wk, 12th wk and after discontinuing treatment 4 wks Hemi-mMASI score,Melasma 4th wk, 8th wk, 12th wk and after discontinuing treatment 4 wks Melanin index,Melasma 4th wk, 8th wk, 12th wk Physician global assessment score | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effect 4th wk, 8th wk, 12th wk and after discontinuing treatment 4 wks Investigator assesment,Patient satisfaction after completing of treatment (12 weeks) Patient assessment | — |
Countries
Thailand
Contacts
Public ContactApinya Sripha
Institute of dermatology
Outcome results
None listed